Thrombopoietin in patients with hepatoblastorna

Emiko Komura, Takafumi Matsumura*, Takashi Kato, Tomoyuki Tahara, Yuko Tsunoda, Tadashi Sawada


研究成果: Article査読

43 被引用数 (Scopus)


Marked thrombocytosis (over 50 x 104/μl) is frequently seen in patients with hepatoblastoma. Thrombopoietin (TPO), c-mpl ligand, has recently been purified as the major physiological regulator of the thrombopoiesis and is mainly produced in the liver. Since it is possible that TPO participates in thrombocytosis and the tumor growth of this particular hepatic tumor, serum TPO levels in addition to interleukin 1β (IL-1β) and IL-6 levels were assessed in seven untreated patients by using a sandwich enzyme-linked immunosorbent assay. High serum TPO levels were observed in all of the examined patients. The level ranged from 3.15 to 11.02 (mean ± standard deviation; 6.08 ± 1.25) fmol/ml. IL-6 levels were also somewhat higher than normal. Platelet counts, however, appeared to correlate more with serum TPO levels (p = 0.1) than with IL-1β (p = 0.5) and IL-6 (p = 0.2) levels. Furthermore, using the reverse transcriptase polymerase chain reaction method, the expression of c-mpl mRNA was found in five of eight hepatoblastoma tissues as well as TPO mRNA in all eight tissues. These observations suggest that thrombocytosis in hepatoblastoma patients results from the production of cytokine members, including TPO, within tumor tissues. Additionally, it is possible that TPO might act as a type of autocrine and/or paracrine system for cellular growth in this tumor.

出版ステータスPublished - 1998

ASJC Scopus subject areas

  • 分子医療
  • 発生生物学
  • 細胞生物学


「Thrombopoietin in patients with hepatoblastorna」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。